Why has it been so difficult to prove the efficacy of alpha-I-antitrypsin replacement therapy? Insights from the study of disease pathogenesis

Drug Design, Development and Therapy

Volumn 5, Issue , 2011, Pages 391-405

  Dickens, Jennifer A ^a   Lomas, David A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

1 antitrypsin deficiency; Augmentation therapy; Emphysema

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME REPLACEMENT; GENE MUTATION; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; LUNG DISEASE; LUNG TRANSPLANTATION; OUTCOME ASSESSMENT; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN POLYMERIZATION; PROTEIN PROCESSING; PROTEIN SECRETION; RESPIRATORY TRACT INFLAMMATION; REVIEW; TREATMENT INDICATION; BLOOD; CLINICAL TRIAL (TOPIC); EMPHYSEMA; GENETICS; INFLAMMATION; MUTATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; CLINICAL TRIALS AS TOPIC; EMPHYSEMA; HUMANS; INFLAMMATION; LUNG DISEASES; MUTATION; TREATMENT OUTCOME;

EID: 84856144387     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S14018     Document Type: Review

References (137)

1. 1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963;15: 132-140.
2. Sharp HL, Bridges RA, Krivit W, Freier EF. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med. 1969;73(6):934-939.
3. 1-antitrypsin deficiency: evaluation of bronchiectasis with CT. Radiology. 1996;199(1):137-141.
4. Eden E, Mitchell D, Mehlman B, et al. Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med. 1997;156(1):68-74.
5. Griffith ME, Lovegrove JU, Gaskin G, Whitehouse DB, Pusey CD. C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and the P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant. 1996;11(3):438-443.
6. Bleumink E, Klokke AH. Relationship between Weber-Christian panniculitis and the ZZ phenotype of alpha1-antitrypsin. Arch Dermatol Res. 1985;277(4):328-329.
7. 1-proteinase inhibitor by human-derived epithelial cells. J Biol Chem. 1997;272(13): 8250-8255.
8. Venembre P, Boutten A, Seta N, et al. Secretion of alpha 1-antitrypsin by alveolar epithelial cells. FEBS Lett. 1994;346(2-3):171-174.
9. Geboes K, Ray MB, Rutgeerts P, Callea F, Desmet VJ, Vantrappen G. Morphological identification of alpha-1-antitrypsin in the human small intestine. Histopathology. 1982;6(1):55-60.
10. Paakko P, Kirby M, du Bois RM, Gillissen A, Ferrans VJ, Crystal RG. Activated neutrophils secrete stored alpha-1 antitrypsin. Am J Respir Crit Care Med. 1996;154(6 pt 1):1829-1833.
11. Cohen AB. Interrelationships between the human alveolar macrophage and alpha-1-antitrypsin. J Clin Invest. 1973;52(11):2793-2799.
12. Cox DW, Woo SL, Mansfield T. DNA restriction fragments associated with alpha 1-antitrypsin indicate a single origin for the deficiency allele PI Z. Nature. 1985;316(6023):79-81.
13. 1-antitrypsin deficiency in European countries. Eur Respir J. 2006; 27(1):77-84.
14. de Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest. 2002;122(5);1818-1829.
15. Seyama K, Nukiwa T, Souma S, Shimizu K, Kira S. Alpha 1-antitrypsin-deficient variant Siiyama (Ser53[TCC] to Phe53[TTC]) is prevalent in Japan. Status of alpha 1-antitrypsin deficiency in Japan. Am J Respir Crit Care Med. 1995;152(6 pt 1):2119-2126.
16. Ferrarotti I, Baccheschi J, Zorzetto M, Tinelli C, Corda L, Balbi B, et al. Prevalence and phenotype of subjects carrying rare variants in the Italian registry for alpha1-antitrypsin deficiency. J Med Genet. 2005; 42(3):282-287.
17. Lee JH, Brantly M. Molecular mechanisms of alpha1-antitrypsin null alleles. Respir Med. 2000;94(Suppl C):S7-S11.
18. 1-antitrypsin accumulation in the liver. Nature. 1992;357(6379): 605-607.
19. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, PiZ. Acta Med Scand. 1798;204(5):345-351.
20. Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986;89(3):370-373.
21. Gadek JE, Klein HG, Holland, PV, Crystal RG. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest. 1981;68(5):1158-1165.
22. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev. 2010;7: CD007851.
23. 1-antitrypsin causes a protein folding defect. Nat Struct Biol. 1995;2(5):363-367.
24. 1-antitrypsin. J Biol Chem. 1997;272(1): 510-516.
25. 1-antitrypsin is preferentially selected for degradation. Proc Natl Acad Sci U S A. 2003;100(14): 8229-8234.
26. Kroeger H, Miranda E, MacLeod I, et al. Endoplasmic reticulum-associated degradation (ERAD) and autophagy cooperate to degrade polymerogenic mutant serpins. J Biol Chem. 2009;284(34):22793-22802.
27. 1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem. 1996;271(37):22791-22795.
28. Le A, Ferrell GA, Dishon DS, Le QQ, Sifer RN. Soluble aggregates of the human PiZ á1-antitrypsin variant are degraded within the endoplasmic reticulum by a mechanism sensitive to inhibitors of protein synthesis. J Biol Chem. 1992;267(2):1072-1080.
29. Gooptu B, Hazes B, Chang WS, et al. Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates two-stage insertion of the reactive loop: implications for inhibitory function and conformational disease. Proc Natl Acad Sci U S A. 2000;97(1):67-72.
30. 1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemo-tactic in vivo. Am J Path. 2005;166(2):377-386.
31. Gross B, Grebe M, Wencker M, Stoller JK, Bjursten LM, Janciauskiene S. New findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy. Dermatology. 2009;218(4):370-375.
32. 1-antitrypsin and its polymers. Ann Rheum Dis. 2011. In press.
33. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8(7):519-529.
34. Pahl HL, Sester M, Burgert HG, Baeuerle PA. Activation of transcription factor NF-kappaB by the adenvirus E3/19 K protein requires its ER retention. J Cell Biol. 1996;132(4):511-522.
35. 1-antitrypsin within the hepatic endoplasmic reticulum does not elevate the steady-state level of grp78/BiP. J Biol Chem. 1990; 265(33):20463-20468.
36. 1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and-12, NF-κB, and BAP31 but not the unfolded protein response. J Biol Chem. 2005;280(47):39002-39015.
37. Davies MJ, Miranda E, Roussel BD, Kaufman RJ, Marciniak SJ, Lomas DA. Neuroserpin polymers activate NF-kappaB by a calcium signalling pathway that is independent of the unfolded protein response. J Biol Chem. 2009;284(27):18202-18209.
38. 1-antitrypsin deficiency. J Immunol. 2004;172(9):5722-5726.
39. Rudnick DA, Liao Y, An JK, Muglia LJ, Perlmutter DH, Teckman JH. Analyses of hepatocellular proliferation in a mouse model of α-1-antitrypsin deficiency. Hepatology. 2004;39(4):1048-1055.
40. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med. 1976;294(24):1316-1321.
41. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha1-antitrypsin deficiency. N Engl J Med. 1986;314(12):736-739.
42. Hashemi M, Alavian SM, Ghavami S, et al. High prevalence of alpha 1 antitrypsin phenotypes in viral hepatitis B infected patients in Iran. Hepatol Res. 2005;33(4):292-297.
43. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900.
44. Bowlus CL, Willner I, Zern MA, et al. Factors associated with advanced liver disease in adults with alpha-1-antitrypsin deficiency. Clin Gastroenterol Hepatol. 2005;3(4):390-396.
45. Kemmer N, Kaiser T, Zacharias V, Neff GW. Alpha-1-antitrpysin deficiency: outcomes after liver transplantation. Transplant Proc. 2008; 40(5):1492-1494.
46. McElvaney NG, Stoller JK, Buist AS, et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest. 1997;111(2):394-403.
47. Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med. 1994;61(6):461-467.
48. Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest. 2005;128(4):1989-1994.
49. Janus ED, Phillips NT, Carrell RW. Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet. 1985;1(8421):152-154.
50. Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med. 2001;164(10 pt 1):1805-1809.
51. Mayer AS, Stoller JK, Bucher BB, et al. Occupational exposure risks in individuals with PI*Z alpha(1)-antitrypsin deficiency. Am J Respir Crit Care Med. 2000;162(2 pt 1):553-538.
52. Bamforth FJ, Kalsheker NA. Alpha 1 antitrypsin deficiency due to Pi null: clinical presentation and evidence for molecular heterogeneity. J Med Genet. 1988;25(2):83-87.
53. Stockley RA. Measurement of soluble proteins in lung secretions. Thorax. 1984;39(4):241-247.
54. Elliott PR, Bilton D, Lomas DA. Lung polymers in Z α-1-antitrypsin deficiency-related emphysema. Am J Respir Cell Mol Biol. 1998;18(5):670-674.
55. Mulgrew AT, Taggart CC, Lawless MW, et al. Z α-1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest. 2004;125(5):1952-1957.
56. Alam S, Li Z, Janciauskiene S, Mahadeva R. Oxidation of Z{alpha}1-antitrypsin by cigarette smoke induces polymerisation: a novel mechanism of early-onset emphysema. Am J Respir Cell Mol Biol. 2010. [Epub ahead of print].
57. Parmar JS, Mahadeva R, Reed BJ, et al. Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol. 2002;26(6):723-730.
58. Woolhouse IS, Bayley DL, Stockley RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8. Thorax. 2002;57(8):709-714.
59. Hubbard RC, Fells G, Gadek J, Pacholok S, Humes J, Crystal RG. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest. 1991;88(3):891-897.
60. Ogushi F, Fells GA, Hubbard RC, Straus SD, Crystal RG. Z-type alpha 1-antitrypsin is less competent than M1-type alpha-1 antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest. 1987;80(5):1366-1374.
61. Johnson D, Travis J. The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center. J Biol Chem. 1979;254(10):4022-4026.
62. Li Z, Alam S, Wang J, Sandstrom CS, Janciauskiene S, Mahadeva R. Oxidized alpha1-antitrypsin stimulates the release of monocyte chemotactic protein-1 from lung epithelial cells: potential role in emphysema. Am J Physiol Lung Cell Mol Physiol. 2009;297(2):L388-L400.
63. Petrache I, Fijalkowska I, Medler TR, et al. Alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol. 2006;169(4):1155-1166.
64. Blanco I, Lara B, de Serres F. Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema. Orphanet J Rare Dis. 2011;6:14.
65. Wilcke JT, Dirksen A. The effect of inhaled glucocorticosteroids in emphysema due to alpha1-antitrypsin deficiency. Respir Med. 1997; 91(5):275-279.
66. Corda L, Bertella E, La Piana GE, Boni E, Redolfi S, Tantucci C. Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficieny-related COPD. Respiration. 2008;76(1):61-68.
67. Fishman A, Martinez F, Naunheim, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348(21):2059-2073.
68. Dauriat G, Mal H, Jebrak G, et al. Functional results of unilateral lung volume reduction surgery in alpha1-antitrypsin deficient patients. Int J Chron Obstruct Pulmon Dis. 2006;1(2):201-206.
69. Remund KF, Bartosik W, Wood AE, Egan JJ. Endobronchial valve treatment in patients with advanced emphysema and alpha-1-antitrypsin deficiency. Thorax. 2008;63(Suppl VII):A12.
70. The International Society for Heart and Lung Transplantation. Available at: http://www.ishlt.org/registries. Accessed March 2, 2011.
71. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316(17):1055-1062.
72. Kueppers F. The role of augmentation therapy in alpha-1 antitrypsin deficiency. Curr Med Res Opin. 2011;27(3):579-588.
73. Silverman EK, Sandhaus RA. Clinical Practice: alpha1-antitrypsin deficiency. N Engl J Med. 2009;360(26):2749-2757.
74. Stoller JK, Fallat R, Schluchter MD, et al. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest. 2003; 123(5):1425-1434.
75. Schmidt EW, Rasche B, Ulmer WT, et al. Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive disease. Am J Med. 1988;84(6A):63-69.
76. 1-antitrypsin deficiency between 1968 and 2003. Chest. 2005;128(3):1179-1186.
77. Feedback on Cochrane review; see ref 20. Available at: http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD007851/frame.html. Accessed August 4, 2011.
78. Hutchinson DC, Hughes MD. Alpha-1-antitrypsin replacement therapy: will its efficacy ever be proved? Eur Respir J. 1997;10(10):2191-2193.
79. 1-antitrypsin deficiency. Am J Respir Crit Care Med. 2000;161(3 pt 1):796-801.
80. 1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997;10(10):2260-2263.
81. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med. 1998;158(1):49-59.
82. 1-protease inhibitor. Chest. 2001;119(3):737-744.
83. Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis. 2009;4:443-452.
84. 1-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160(5 pt 1):1468-1472.
85. Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal RG. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA. 1988;260(9):1259-1264.
86. 1-antitrypsin deficiency. Eur Respir J. 2009;33(6):1345-1353.
87. Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor (API) Deficiency. ClinicalTrials.gov Identifier: NCT00261833.
88. Chapman KR, Bradi AC, Paterson D, et al. Slower lung function decline during augmentation therapy in patients with alpha 1-antitrypsin efficiency (A1ATD): results from the Canadian AIR registry. Proc Am Thorac Soc. 2005:A808.
89. Chapman KR, Stockley RA, Dawkins C, et al. Augmentation therapy for alpha1-antitrypsin deficiency: a meta-analysis. COPD. 2009;6(3): 177-184.
90. Stockley RA, Parr DG, Piitulainen E, et al. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res. 2010;11:136.
91. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest. 2000;118(5):1480-1485.
92. Campos MA, Alazemi S, Zhang G, et al. Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy. Respir Med. 2009;103(10):1532-1539.
93. 1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002;165(11):1494-1498.
94. 1-antitrypsin deficiency as assessed by annual CT. Acta Radiol. 1997;38(5):826-832.
95. Voulgari F, Cummins P, Gardecki TI, Beeching NJ, Stone PC, Stuart J. Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery and infection. Br Heart J. 1982;48(4):352-356.
96. Schwarzenburg SJ, Sharp HL, Berry SA, Manthei RD, Seelig S. Hormonal regulation of serum alpha 1-antitrypsin and hepatic alpha 1-antitrypsin mRNA in rats. Biochem Biophys Res Commun. 1987; 147(3):936-941.
97. 1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem. 2007;50(22):5357-5363.
98. 1-antitrypsin and liver cirrhosis. J Clin Invest. 1999; 103(7):999-1006.
99. 1-antitrypsin deficiency. Hepatology. 2010;52(3):1078-1088.
100. Poller W, Merklein F, Schneider-Rasp S, et al. Molecular characterization of the defective alpha 1-antitrypsin alleles PI Mwurzburg (Pro369Ser), Mheerlen (Pro369 Leu), and Q0lisbon (Thr68Ile). Eur J Hum Genet. 1999;7(3):321-331.
101. Fraizer GC, Harrold TR, Hofker MH, Cox DW. In-frame single codon deletion in the Mmalton deficiency allele of a1-antitrypsin. Am J Hum Genet. 1989;44(6):894-902.
102. Curiel DT, Vogelmeier C, Hubbard RC, Stier LE, Crystal RG. Molecular basis of alpha 1-antitrypsin deficiency and emphysema associated with the alpha 1-antitrypsin Mmineral springs allele. Mol Cell Biol. 1990;10(1):47-56.
103. Matsunaga E, Shiokawa S, Nakamura H, Maruyama T, Tsuda K, Fukumaki Y. Molecular analysis of the gene of the alpha 1-antitrypsin deficiency variant, Mnichinan. Am J Hum Gene. 1990;46(3):602-612.
104. Faber J-P, Poller W, Weidinger S, et al. Identification and DNA sequence analysis of 15 new alpha-1 antitrypsin variants, including 2 PiQO alleles and one deficient PiM allele. Am J Hum Genet. 1994; 55(6):1113-1121.
105. Takahashi H, Nukiwa T, Satoh K, et al. Characterization of the gene and protein of the alpha 1-antitrypsin "deficiency" allele Mprocida. J Biol Chem. 1988;263(30):15528-15534.
106. Jardi R, Rodriguez-Frias F, Lopez-Talavera JC, et al. Characterization of the new alpha-1-antitrypsin-deficient PI M-type allele, PI M(vall d'hebron) (Pro(369)--.Ser). Hum Hered. 2000;50(5):320-321.
107. Coni P, Pili E, Convertino G, et al. MVarallo: a new M(Like) alpha 1-antitrypsin-deficient allele. Diagn Mol Pathol. 2003;12(4):237-239.
108. Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to antithrombin. Alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med. 1983;309(12):694-698.
109. Faber JP, Weidinger S, Goedde HW, Ole K. The deficient alpha-I-antitrypsin phenotype PI P is associated with an A-to-T transversion in exon III of the gene. Am J Hum Genet. 1989;45(1):161-163.
110. Graham A, Kalsheker NA, Newton CR, Bamforth FJ, Powell SJ, Markham AF. Molecular characterisation of three alpha-1-antitrypsin deficiency variants: proteinase inhibitor (Pi) nullcardiff (Asp256----Val); PiMmalton (Phe51----deletion) and PiI (Arg39----Cys). Hum Genet. 1989;84(1):55-58.
111. Hildesheim J, Kinsley G, Bissell M, Pierce J, Brantly M. Genetic diversity from a limited repertoire of mutations on different common allelic backgrounds: alpha 1-antitrypsin deficiency variant Pduarte. Hum Mutat. 1993;2(3):221-228.
112. Coli A, Bigotti G. Alpha-1-antitrypsin protease inhibitor SZ phenotype and liver cirrhosis. Appl Pathol. 1989;7(1):54-60.
113. Holme J, Stockley RA. CT scan appearance, densitometry, and health status in protease inhibitor SZ alpha1-antitrypsin deficiency. Chest. 2009;136(5):1284-1290.
114. 1-antitrypsin PI S and PI Z frequencies in countries outside Europe: a meta-analysis. Clin Genet. 2001;60(6):431-441.
115. Yuasa I, Sugimoto Y, Ichinose M, et al. PI*S(iiyama), a deficiency gene of alpha 1-antitrypsin: evidence for the occurrence in western Japan. Jpn J Hum Genet. 1993;38(2):185-191.
116. Holmes MD, Brantly ML, Fells GA, Crystal RG. Alpha 1-antitrypsin Wbethesda: molecular basis of an unusual alpha 1-antitrypsin deficiency variant. Biochem Biophys Res Commun. 1990;170(3):1013-1020.
117. Jardi R, Rodriguez F, Miravitlles M, et al. Identification and molecular characterization of the new alpha-1-antitrypsin deficient allele PI Y barcelona (Asp256--.Val and Pro391--.His). Mutations in brief no.174. Online. Hum Mutat. 1998;12(3):213.
118. 1-antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest. 2010;138(5):1125-1132.
119. Graziadei IW, Joseph JJ, Wiesner RH, Therneau TM, Batts KP, Porayko MK. Increased risk of chronic liver failure in adults with heterozygous alpha1-antitrypsin deficiency. Hepatology. 1998;28(4):1058-1063.
120. Weidinger S, Jahn W, Cujnik F, Schwarzfischer F. Alpha-1-antitrypsin: evidence for a fifth PI M subtype and a new deficiency allele PI*Z augsburg. Hum Genet. 1985;71(1):27-29.
121. Whitehouse DB, Abbott CM, Lovegrove JU, et al. Genetic studies on a new deficiency gene (PI*Ztun) at the PI locus. J Med Genet. 1989;26(12):744-749.
122. Graham A, Kalsheker NA, Bamforth FJ, Newton CR, Markham AF. Molecular characterisation of two alpha-1-antitrypsin deficiency variants: proteinase inhibitor (Pi) Null(Newport) (Gly115----Ser) and (Pi) Z Wrexham (Ser-19----Leu). Hum Genet. 1990;85(5):537-540.
123. Satoh K, Nukiwa T, Brantly M, et al. Emphysema associated with complete absence of alpha 1-antitrypsin in serum and the homozygous inheritance [corrected] of a stop codon in an alpha 1-antitrypsin-coding exon. Am J Hum Genet. 1988;42(1):77-83.
124. Fraizer GC, Harrold TR, Hofker MH, Cox DW. In-frame single codon deletion in the Mmalton deficiency allele of alpha 1-antitrypsin. Am J Hum Genet. 1989;44(6):894-902.
125. Zorzetto M, Ferrarotti I, Campo I, et al. Identification of a novel alpha1-antitrypsin null variant (Q0Cairo). Diagn Mol Pathol. 2005;14(2):121-124.
126. Brantly M, Lee JH, Hildesheim J, et al. Alpha1-antitrypsin gene mutation hot spot associated with the formation of a retained and degraded null variant. Am J Respir Cell Mol Biol. 1997;16(3):225-231.
127. Nukiwa T, Takahashi H, Brantly M, Courtney M, Crystal RG. alpha 1-Antitrypsin nullGranite Falls, a nonexpressing alpha 1-antitrypsin gene associated with a frameshift to stop mutation in a coding exon. J Biol Chem. 1987;262(25):11999-12004.
128. Sifers RN, Brashears-Macatee S, Kidd VJ, Muensch H, Woo SL. A frameshift mutation results in a truncated alpha 1-antitrypsin that is retained within the rough endoplasmic reticulum. J Biol Chem. 1988; 263(15):7330-7335.
129. Takahashi H, Crystal RG. Alpha 1-antitrypsin Null (isola di procida): an alpha 1-antitrypsin deficiency allele caused by deletion of all alpha 1-antitrypsin coding exons. Am J Hum Genet. 1990;47(3):403-413.
130. Frazier GC, Siewertsen MA, Hofker MH, Brubacher MG, Cox DW. A null deficiency allele of alpha 1-antitrypsin, QOludwigshafen, with altered tertiary structure. J Clin Invest. 1990;86(6):1878-1884.
131. Curiel D, Brantly M, Curiel E, Stier L, Crystal RG. Alpha-1-antitrypsin deficiency caused by the alpha-1-antitrypsin nullmattawa gene. J Clin Invest. 1989;83(4):1144-1152.
132. Vaz Rodrigues L, Costa F, Marques P, Mendonça C, Rocha J, Seixas S. Severe α-1 antitrypsin deficiency caused by Q0(Ourém) allele: clinical features, haplotype characterization and history. Clin Genet. 2011. [Epub ahead of print].
133. Poller W, Faber JP, Weidinger S, Olek K. DNA polymorphisms associated with a new alpha 1-antitrypsin PIQ0 variant (PIQ0riedenburg). Hum Genet. 1991;86(5):522-524.
134. Lee J, Novoradovskaya N, Rundquist B, Rewine J, Saltini C, Brantly M. Alpha-1-antitrypsin nonsense mutation associated with retained truncated protein and reduced mRNA. Mol Genet Metab. 1998;63(4):270-280.
135. Laubach VE, Ryan WJ, Brantly M. Characterization of a human alpha 1-antitrypsin null allele involving aberrant mRNA splicing. Hum Mol Genet. 1993;2(7):1001-1005.
136. Lomas DA, Belorgey D, Mallya M, et al. Molecular mousetraps and the serpinopathies. Biochem Soc Trans. 2005;33(pt 2):321-330.
137. Lomas DA, Finch JT, Seyama K, Nukiwa T, Carrell RW. Alpha1-antitrypsin Siiyama (Ser53Phe). Further evidence for intracellular loop-sheet polymerization. J Biol Chem. 1993;268(21):15333-15335.